Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;18(1):52-6.
doi: 10.1177/1078155210389218. Epub 2010 Nov 25.

Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009

Affiliations

Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009

Philip Savage. J Oncol Pharm Pract. 2012 Mar.

Abstract

Over the past decade, 23 new cancer treatment drugs have been introduced, many have brought major benefits to patient care, whilst others have maintained clinical benefits with reduced toxicity. In this article, the historical trends in drug numbers, therapeutic classification, and treatment costs have been reviewed. Drugs are classified by years of introduction, therapeutic classification, and an assessment of relative treatment cost using a contemporary 'standard' treatment compared with the relevant UK GDP per capita. Prior to 1960, there were 5 cancer drugs available, 2 new drugs were introduced in the 1960s, 18 in the 1970s, 14 in the 1980s, 24 in the 1990 s, and 23 in the past decade. Prior to 1975, all the cancer treatments were classical cytotoxic agents. Since then, there have been 17 hormonal agents, 6 monoclonal antibodies, and 7 targeted therapies. The number of new classical cytotoxic drugs has declined dramatically with only one new agent in the past decade. The new drugs have become increasingly expensive relative to average GDP, with an average standard course of treatment with a new non-hormonal agent costing 34% of per capita GDP in 1995-1999, 53% in 2000-2004, and 67% in 2005-2009. In contrast, the cost of new hormonal agents introduced has remained at lower levels, with 6-month treatment with Degarelix, the newest hormonal agent, costing 3.8% of per capita GDP in 2009. The data in this article may be of value to those interested in the history of cancer treatment development and associated economic issues.

PubMed Disclaimer

Substances

LinkOut - more resources